We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Biosensor Chip Enables High-Sensitivity Protein Analysis for Disease Diagnosis

By LabMedica International staff writers
Posted on 19 May 2010
In the fight against cancer and other diseases, precise analysis of specific proteins can lead the way toward targeted treatments. More...
Scientists have now developed an innovative biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can reveal if these proteins are altered through the influence of disease or drugs.

The human immune system recognizes pathogens by specific proteins on their surfaces. This detection principle manifests itself repeatedly in biology, and it is already used in medical tests. Such tests typically require relatively large amounts of sample material, however, and many problems cannot be examined in this manner. For some tests, the target protein must be chemically modified by reagents. That requires both time and well-trained lab technicians. Scientists from the Technische Universitaet Muenchen's (TUM; Germany) Walter Schottky Institute, together with Fujitsu Laboratories (Kawasaki, Japan), have developed a biosensor 100 times more sensitive than currently available tests in recognizing proteins that are characteristic for the clinical depiction of specific diseases.

The biosensor chip holds synthetic DNA molecules, which are negatively charged, in an aqueous salt solution. These long molecules are tied at one end to a gold surface. The free end is labeled with a fluorescent marker, so it can be optically observed; and at the very tip, the scientists can place a "capture probe,” a molecule that fits together with the target protein similar to a key in a lock. Alternating electric potentials set the DNA molecules in motion, swinging back and forth between "standing” and "lying” states with regular changes in a tightly confined but intense field. If the protein of interest is present in sample material placed on the biosensor chip, it will bind to the "key” molecule. Moreover, because this makes the DNA strands considerably heavier, their swinging motion will be clearly slower. Exact validation of the identity of the captured protein can be construed from measurements of this motion, since both the size and shape of the protein will affect the way the DNA molecules swing.

This approach is unique in its ability not only to determine the concentration of the target protein, but also to show if it is altered by the disease or the influence of medication. The scientists are currently working with a chip that can analyze 24 different proteins in parallel. "The potential to analyze, on a single chip, many proteins at once in terms of multiple parameters represents a significant advance,” noted Dr. Ulrich Rant, head of the project. Dr. Rant is a researcher in the laboratories of Prof. Gerhard Abstreiter at the Walter Schottky Institute, a central institute of TUM focused on the fundamental physics of semiconductor electronics.

Significant application areas for this biosensor chip technology, which the TUM scientists have named "switchSENSE,” include medical diagnostics, pharmaceutical drug development, and proteomics research. It could eventually make its way into the doctor's office, as a simple and quick analysis tool for identifying infectious diseases.

Dr. Rant and his team have founded a startup company to commercialize their development, supported by the Technische Universitaet Muenchen and their industrial partner Fujitsu Laboratories, Ltd. Further development is targeted toward completion of a pre-production prototype by the end of 2010 and collaborative pilot projects with customers in the biotechnology and pharmaceutical sectors.

Related Links:

Technische Universitaet Muenchen's
Fujitsu Laboratories



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.